European Thyroid Association (ETA) and Thyroid Federation International (TFI) Joint Position Statement on the Interchangeability of Levothyroxine Products in EU Countries

Several European countries have seen major health issues after a switch from one levothyroxine brand to another, as well as following the introduction of several levothyroxine formulation changes. While the relationship between these health issues and brand or formulation changes merits further inve...

Full description

Saved in:
Bibliographic Details
Published inEuropean thyroid journal Vol. 7; no. 5; pp. 238 - 242
Main Authors Fliers, Eric, Demeneix, Barbara, Bhaseen, Ashok, Brix, Thomas H.
Format Journal Article
LanguageEnglish
Published Basel, Switzerland S. Karger AG 01.10.2018
Subjects
Clinical Thyroidology / Review
Thyroid Federation International
Health issues
European Thyroid Association
Levothyroxine products
Online AccessGet full text

Cover

More Information
Summary:Several European countries have seen major health issues after a switch from one levothyroxine brand to another, as well as following the introduction of several levothyroxine formulation changes. While the relationship between these health issues and brand or formulation changes merits further investigation, the current position statement on behalf of both health-care providers and patients summarizes recent events in several European countries and provides a number of recommendations to limit the burden for patients, so as to prevent increased health-care consumption and health-care expenses in this context.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
A. Bhaseen: on behalf of the Thyroid Federation International. E. Fliers, B. Demeneix, T.H. Brix: on behalf of the Executive Committee of the European Thyroid Association.
ISSN:2235-0640
2235-0802
DOI:10.1159/000493123